Tuesday, July 7, 2026
← Back to archivePolicy
Policy•KFF•Jul 7, 2026
AI: Rewiring the Machine
background ▾
- •Industry leaders recognize EHR systems require architectural redesign to effectively integrate AI capabilities
Oracle Health
→ Read original articlePolicy•STAT News•Jul 7, 2026
5 takeaways from STAT’s series on the soaring cost of health insurance
background ▾
- •Health insurance premium costs have increased 10.5-fold since 1987 to $1.4 trillion annually, vastly outpacing inflation and eroding worker earnings
- •Small businesses face a disproportionate cost burden with deductibles 50% higher than large firms, leading to declining coverage offerings (below 60% of firms with ≤200 employees)
- •Monitor congressional action on subsidy renewal and potential legislative responses to employer-sponsored insurance affordability crisis, which could reshape pharmaceutical market access and payer negotiations
Policy•STAT News•Jul 7, 2026
Opinion: What if this Ebola outbreak can’t be stopped?
background ▾
- •No proven medical countermeasures exist for the Bundibugyo Ebola strain currently circulating in the DRC, a critical gap in available tools.
- •Global health containment strategy has shifted from coordinated eradication toward isolationist border control, an approach the author argues historically fails without upstream outbreak control.
- •Monitor whether WHO/CDC capacity constraints and ongoing DRC conflict materially impair outbreak response effectiveness, and track development status of Bundibugyo-specific antivirals or vaccines.
Policy•STAT News•Jul 7, 2026
Opinion: Medicine thinks Gen Z is too soft. It’s wrong
background ▾
- •This is an opinion column with no direct impact on pharma policy, market access, or clinical trials—it falls outside core industry news categories
Policy•KFF•Jul 6, 2026
Medicare Advantage Insurers Deny Prior Authorization Requests for Post Acute Care at Substantially Higher Rates Than the Overall Denial Rate
background ▾
- •Medicare Advantage insurers deny 65% of LTCH and 54% of IRF prior authorization requests versus <8% overall MA denial rate, disproportionately affecting sicker, more vulnerable beneficiaries
- •High appeal overturn rates (95% for SNFs, 43% for IRFs, 36% for LTCHs) suggest systematic inappropriate initial denials and indicate prior authorization is being used as a cost-containment tool with limited clinical justification
- •Watch for potential regulatory action: CMS may strengthen MA oversight, implement prior authorization standards, or expand traditional Medicare's testing of AI-based prior authorization to address equity and access gaps
Medicare Advantage insurers (unnamed; general category)
→ Read original articleMarket Access
Market Access•Fierce Biotech•Jul 6, 2026
Genentech lays off 103 alongside gRED rethink, pens $490M breast cancer collab
background ▾
- •Genentech is executing a targeted workforce reduction (103 positions) as part of broader restructuring at the Roche subsidiary, following 489+ layoffs in 2023-2024, signaling ongoing portfolio and organizational realignment under parent company Roche.
- •The $490M Astex collaboration targets breast cancer drug discovery via fragment-based platforms, building on Astex's track record with blockbuster precedents (Kisqali with Novartis) and attracting multiple Big Pharma partners.
- •Monitor whether gRED restructuring improves Genentech's early-stage pipeline velocity and whether the Astex partnership yields clinical candidates within 3-5 years, particularly for cell-cycle regulator targets.
GenentechRocheAstex PharmaceuticalsKisqali
→ Read original articleMarket Access•Endpoints News•Jul 7, 2026
French gene therapy biotech gets €33M to follow Krystal's blueprint
background ▾
- •HSV-based gene therapy continues to attract investor capital following Krystal Biotech's commercial validation of the platform
- •Competitive pressure is building in the HSV gene therapy space as multiple players advance toward clinical and commercial stages
Krystal Biotech
→ Read original articleMarket Access•Fierce Biotech•Jul 6, 2026
Scribe notes down IPO ambition to fund lipid-lowering genetic meds through clinical trials
background ▾
- •STX-1150 represents a novel gene-silencing approach (not traditional gene editing) targeting PCSK9 with potential for ultra-long dosing intervals (every 10-20 years vs. semi-annual for Leqvio), positioning it as a potential end-state therapy if efficacy is confirmed
- •First-in-human data in H1 2027 will be critical; if STX-1150 demonstrates meaningful LDL-C lowering in the 64-patient Australian trial, competitive positioning against Repatha/Leqvio strengthens substantially
- •Watch IPO pricing and underwriter confidence—biotech IPO momentum is strong but Scribe's pipeline is early-stage (preclinical partnerships, one Phase 1 program); successful pricing will signal investor appetite for early CRISPR genetic medicine platforms in cardiovascular disease
Scribe TherapeuticsBiogenAmgenSTX-1150STX-1200STX-1400
→ Read original articleMarket Access•Endpoints News•Jul 6, 2026
Vertex makes $10B deal for commercial endocrinology biotech Crinetics
background ▾
- •Vertex's largest-ever acquisition ($10B) represents a major strategic pivot toward commercial endocrinology and portfolio diversification
- •Crinetics brings established marketed products and a clinical-stage pipeline to Vertex's portfolio, addressing the company's need for revenue diversification beyond CF
- •Watch for regulatory approvals, pipeline advancement updates on Crinetics' clinical candidates, and integration progress announcements over the next 12-24 months
Vertex PharmaceuticalsCrinetics Pharmaceuticals
→ Read original articleMarket Access•STAT News•Jul 6, 2026
Obamacare rolls shrank dramatically in many states over the past year, new federal data shows
background ▾
- •ACA enrollment fell by 2.6 million people nationally following expiration of enhanced subsidies, with certain states losing over 32% of enrollees, signaling a major reduction in the subsidized insurance market and likely increase in the uninsured population.
- •Most analysts believe departing ACA enrollees are becoming uninsured rather than transitioning to employer coverage, as the marketplace is typically a 'place of last resort'—reducing drug utilization and creating access barriers for chronic disease management.
- •Watch for pharma industry responses: potential shifts in patient assistance programs, changes to formulary negotiations with ACA insurers facing reduced enrollment, and increased pressure on Medicaid programs as a safety net for newly uninsured patients.
Clinical Trials
Clinical Trials•Endpoints News•Jul 6, 2026
Bristol Myers details Krazati confirmatory study failure in colorectal cancer
background ▾
- •Krazati confirmatory trial failure in colorectal cancer eliminates a key label expansion opportunity and raises questions about the drug's broader applicability beyond GIST
- •This setback reduces Bristol Myers' near-term pipeline momentum and may impact investor expectations for Krazati's peak sales potential
- •Bristol Myers will likely announce next steps regarding Krazati development strategy, including potential pivot to other indications or trial designs
Bristol Myers SquibbKrazati
→ Read original article